There are no conflicts of interest to report. respectively. Overall, our database provides a resource of pharmacological data that can reinforce known therapeutic strategies and identify novel drugs and drug targets across multiple cancer types.
Introduction
DNA methylation is an heritable epigenetic event occurring at cytosines 5' of guanosines (CpG's) and catalyzed by DNA methyltransferases (DNMT), which transfer a methyl group from S-adenosyl methionine to the 5 position of the Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 6, 2016; DOI: 10.1158/0008-5472. cytosine ring (1) . DNA methylation is involved in multiple epigenetic processes ranging from transcriptional down-regulation, X chromosome inactivation, embryonic development, and genomic imprinting (2, 3) . "CpG islands" in the 5' regulatory regions of many genes (~56%), are involved in transcription downregulation and histone deacetylase recruitment (4, 5) . The pattern of methylation has both allele-specific and evolutionary conservation, as well as tissue-specific and cell-specific variations (6) (7) (8) .
DNA methylation defects have been associated with multiple diseases including i) global methylation defects for diabetes, obesity, fetal alcohol syndrome and aging, ii) imprinting disorders for Angelman syndrome, Prader-Wili syndrome, Beckwith-Wiedemann syndrome and autism, iii) genetically-driven methylation defects for Fragile X syndrome, dyslexia, Rett syndrome, centromere instability, Sotos, Weaver, and Kleefstra syndomes, and iv) candidate gene methylation defects for obesity and Type 1 and 2 diabetes (9,10).
DNA methylation defects are also linked to cancers (9) . Global loss of DNA methylation has been associated with genomic instability, loss of imprinting, and reactivation of transposable elements (11) . Loss of genomic imprinting of IGF2 has been associated with increased risk of liver, lung, intestinal and colon cancers (3) . Concurrent with global hypomethylation, specific hypermethylation of tumor suppressor genes, including CDKN2A, MLH1, VHL, and CDH1 occurs leading to their transcriptional repression (3, 9) .
The NCI-60 was the first cancer cell line database established and it remains the largest drug and most complete source of molecular data (12, 13) . In the current study we provide whole genome methylation levels from 485,577 probes across the NCI-60 cancer cell line panel. We detail probes that are associated with genes, and provide easy access to them using our CellMiner \ Cell line signature web-based application (14) . This allows direct comparison and integration with other molecular and activity data, examples of which are included. We also provide a novel form of visualization of the level of influence on gene transcript levels of DNA methylation and copy number, and examples of the relevance of DNA methylation for predicting the activity of DNA-targeted agents.
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Materials and Methods

Cell lines, growth, and DNA purification
We combined data for the NCI-60 cell lines from both the National Cancer Institute (NCI) and the Cancer Epigenetics and Biology Program (CEBP) (15) .
Both the NCI and CEPB obtained the cell lines from the Developmental Therapeutics Program (DTP) (12, 16, 17) . For the NCI dataset, cells were grown and DNA isolated as described previously (18, 19) . For the CEPB dataset, cells were grown and DNA isolated as described previously (15) .
DNA methylation, comparison of CEBP and DTB datasets, and probe beta values
NCI bisulfite conversion and DNA sample handling was done as described previously (20) . The Infinium HumanMethylation450k BeadChip kit (Illumina, Inc, San Diego, CA, 92122, catalog #WG-314-1001) was used with standard protocol for both the CEBP and NCI studies (20, 21) . CEPB bisulfite conversion and DNA sample handling was done as described (15) .
NCI samples used p-values of detection as filters for each probe. Probes with values of p>0.01 were treated as missing. For dataset comparison, we did average linkage hierarchical clustering of all cell line probe intensity profiles using 1-Pearson correlation distance. This and all subsequent statistical analysis was done in the R statistical environment (22) . We used the probe-wise average of the cell line replicates from the two datasets for all subsequent analysis.
Probe beta values by cell line are calculated as: Probes were assessed for location with respect to genes and proximal CpG islands defined by Illumina. Probes were designated as category-1 or 2 with category-1 considered to be most informative. For subsequent comparisons, category-1 probes were used if available, and if not then category-2. In either case, gene methylation values resulted from averages of those probes. For genes with multiple transcriptional start sites, the transcript with the most negative correlation to the methylation probes was identified and used.
DNA methylation versus transcript expression, and gene group definition
For comparisons between methylation levels and transcript expression z scores, we used the methylation and transcript "Cell line signatures" (16) .
Expression versus methylation correlations, heat-map and histogram were generated using The R Project for Statistical Computing (22) . For the transcript versus methylation analyses by gene category, genes were divided based on correlation value of r < -0.5. Enrichment of Gene Ontology Consortium classifications were accessed using GoMiner with a false discovery rate cut-off off < 0.05 and a minimum ten identified genes per category (23, 24) .
Gene DNA copy number determinations
DNA copy number patterns were determined as described previously (25) . Their gene "Cell line signatures" can be accessed at CellMiner by gene using "CellMiner \ NCI-60 Analysis Tools \ Cell line signature" (16) .
Linear regressions for testing the predictive power of DNA copy number and methylation on transcript expression
For each of the 15,798 genes with all three forms of data available (transcript, methylation and copy number levels) a linear regression model was fit, with both copy number and methylation as independent variables, and transcript expression as the dependent variables. The model provided coefficients for the copy number and methylation that gave the lowest squared error between fitted Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 6, 2016; DOI: 10.1158/0008-5472.CAN-16-0655 6 values and true expression. We separated individual contributions of these two factors for gene expression prediction using the method of relative importance (26) , using the lmg method (27) 
Mutational status of genes
Genetic variants were assessed using the "CellMiner\NCI-60 Analysis Tools \ Cell line signature \ Genetic variant summation" tool (12, 13, 16) . The form of the data used for SMARCB1 in the linear regression analysis is the "Amino acid changing". The form of the data used for MLH1, MSH2, and MSH6 is the "Protein function affecting".
Global methylation and PARP1 and EP300 protein expression levels
The box and whisker plots and linear regression analysis were done using The R Project for Statistical Computing (22) . For the linear regression analysis, the form of KDM2B, CREBBP, and SMARCB1 "Genetic variant summation" data used is the "Amino acid changing". Protein expression for PARP1 and EP300 were accessed using "CellMiner \ NCI-60 Analysis Tools \ Cell line signature \ Protein mean values" (14, 16) .
Pattern comparisons and drug activity determinations
Correlations between median methylation values and cytogenetic measurements of instability were determined using "Pattern comparison", accessed at "CellMiner \ NCI-60 Analysis Tools \ Pattern comparison", within "Miscellaneous phenotypic parameters". Drug "Cell line signatures" can be accessed at CellMiner by National Service Center (NSC) number using "CellMiner \ NCI-60 Analysis Tools \ Cell line signature \ Drug activity z scores" (14, 28) . 
Identification of methylation probes for individual genes
In the NCI dataset analysis, independent from the CEBP team (15) , methylation probes that were gene-specific were selected. To this end, the 485,577 methylation probes on the Infinium HumanMethylation450k BeadChip array were assessed based on location with respect to CpG islands and genes (Supplemental Figure 1A , B, and C) and their relationship with gene expression (Supplemental Figure 1D ). This resulted in a 2-tier probe categorization (Supplemental Figure 1C) probes were the most informative. Category-2 probes were found to be less informative (less well correlated), but still relevant for some genes. As a result, the NCI-60 methylation data for 17,552 genes may be directly retrieved from the CellMiner website (updated to version 2.0) in several forms as described previously (14, 16, 28) . A link providing online instructions for generating DNA methylation Cell line signatures is available (29). The graphical output "Cell line signature's" for 3 examples, VHL, SLFN11, and IRF6, are presented in Figure 2 .
Global methylation levels for the NCI-60
The distribution of global methylation levels for 485,577 probes showed marked differences among individual cell lines ( Figure 3A) . Median values ranged from 17% for melanoma MALME-3M to 84% for colon carcinoma HCT-116. To determine genes that are major contributors in such global differences, the global methylation pattern was compared to epigenetic, chromatin, and histone functional group's (defined in Supplemental Table 2 ) for: i) amino acid changing genetic variants, ii) protein function affecting genetic variants, iii) gene transcript levels, and iv) protein levels, using the "Pattern comparison" web application (14, 28) .
Significant correlations (p<0.01) were found for 24 genes, including five with literature connection to DNA methylation: UHRF1, MTA1, HIST1H1A, PARP1, and EP300. However, none of the 24 significant correlations found could individually predict more than 21% of the median methylation pattern, implying multivariate causation. Using linear regression, it was found that all of these except HIST1H1A made significant contribution to modeling a relationship to the median methylation pattern. After removing HIST1H1A, four other genes (KDM5C, KDM2B, CREBBP, and SMARCB1) were added back, one at a time, based on their appearing in both the epigenetic and chromatin functional categories (Supplemental Table 2 ). Of these, KDM5C and SMARCB1 were found to contribute to the model significantly ( Pattern comparison using the median probe methylation values ( Figure   3A ) identified significant negative correlation to six parameters of genomic instability from cytogenetics (30) . These were modal chromosomal number, numerical complexity, structural heterogeneity, fraction of abnormal chromosomes that experience numerical heterogeneity, fraction of normal chromosomes that experience numerical heterogeneity, and numerical heterogeneity, with correlations of -0.341, -0.362, -0.362, -0.377, -0.389, and -0.425 respectively. These correlations indicate that as the levels of DNA methylation decrease, the levels of genomic instability increase.
Comparison of methylation levels to transcript expression for functional gene groups
Comparison of gene methylation to transcript expression levels across the NCI-60 identified 44 GO categories enriched for genes with significant methylation versus expression correlations (see rows in Figure 4A ) (23, 24) . As these 44 categories had overlapping genes, they were organized into the seven groups shown on the right of Figure 4A , including: metabolic processes, blood coagulation, cell migration and mobility, cell adhesion and assembly, white blood cell proliferation, activation of immune response, cell death and signaling.
Curated gene lists generated from literature for different pathways related to cancer (including epithelial mesenchymal transition, tumor suppressors, oncogenes, apoptosis, DNA repair chromatin and mitochondria; see Supplemental Table 2 ) were also tested. For all the genes in each gene category, the correlation between transcript and methylation levels was computed. The data presented in Figure 4B transcripts with expression and DNA methylation data is shown as the shaded area (see Supplemental Table 2 for individual values).
The epithelial and mesenchymal gene categories, consisting of 25 and 27 genes respectively, were assembled previously (31) . These categories showed the most significant correlation between DNA methylation and transcript levels, with medians of -0.639 and -0.525 for the epithelial and mesenchymal genes, respectively. A wide gap was found prior to the next groups of genes with significant correlation. Those included the genes found by GO analysis (see Figure 4A ), and additional categories including tumor suppressor genes, which were tightly grouped as a cluster of 23 functional groups, within a range of -0.259 to -0.148. By contrast, the microRNAs median value showed a lack of significant correlation to expression (r=0.010). Together, these analyses demonstrate that DNA methylation drives gene expression for selected pathways, such as the epithelial mesenchymal transition (EMT), and to a lesser extend for tumor suppressors in the NCI-60.
Integration of the NCI-60 methylome with transcriptome profiles
Supplemental Table 2 
Integration of DNA methylation and gene expression with gene copy number and mutations across the NCI-60
The majority of the genes (15,798 genes) can be queried for concurrent analyses of DNA methylation, transcript expression, and DNA copy number in the NCI-60 (14) (Supplemental Table 3 ). In Figure 6A , "Cell line signatures" obtained directly from CellMiner for DNA methylation, copy number (14, 25) , and transcript expression (28) , are presented for three exemplary genes for which transcript levels are driven by DNA methylation, copy number of both.
Expression of RAB25, a member of the RAS family involved in membrane trafficking and cell polarity and epithelial phenotype, showed high correlation with methylation (as do other EMT genes see Figure 4B and Figure 5 , top row), but not DNA copy number (r = -0.978 and 0.069, respectively). By contrast, expression of POLG, a housekeeping gene encoding the mitochondrial 
NCI-60 methylome and anticancer pharmacology
MGMT encodes methylguanine methyltransferase, an enzyme that removes O6-methylguanine, the most cytotoxic DNA methylation adduct produced by temozolomide, a commonly used oral drug in glioblastomas (36) . Cancer cells deficient for MGMT are exquisitely sensitive to temozolomide (34) and MGMT promoter methylation is a positive prognostic indicator for temozolomide treatment in glioblastoma (36) . The scatter plot of MGMT methylation versus expression levels (see Figure 5 bottom right) showed significant correlation (r=-0.48). DNA promoter methylation levels above 40% was found associated with MGMT expression levels at background levels (<-0.6) for 81% of those cell lines A second gene, which has recently been causally linked with response to a broad spectrum of DNA damaging drugs (including topoisomerase inhibitors, PARP inhibitors as single agentes or in combination with temozolomide, cisplatin, alkylating agents and DNA synthesis inhibitors) is SLFN11 (Schlafen 11) (15, 32, 33, 37, 38) . SLFN11 encodes a nuclear protein with putative helicase activity that blocks cell cycle progression and dampens DNA repair (32, 39) .
SLFN11 was among the genes with the highest correlation (at the top 94th percentile) between methylation and expression (see Figure 5 bottom right).
Notably, approximately 38% of the NCI-60 cell lines do not express SLFN11 above background level (32) . Of these, lack of SLFN11 expression is linked to methylation in approximately half of the cell lines ( Figure 5) . Neither SLFN11 or MGMT expression had significant association to DNA copy number (p<0.01, Supplemental Table 3 ).
To test whether SLFN11 promoter methylation was linked with resistance to DNA damaging agents, the whole NCI-60 drug database (≈ 21,000 compounds including 108 FDA-approved and 70 clinical trial drugs) was tested.
Drug activity correlations revealed that SLFN11 methylation was significantly correlated with resistance to multiple clinically relevant drugs that cause DNA damage, including alkylating agents (cisplatin, carboplatin, melphalan), topoisomerase I (topotecan, LMP400) and II (etoposide) inhibitors, DNA synthesis inhibitors (gemcitabine, fludarabine, cytarabine, hydroxyurea), PARP inhibitors (talazoparib, olaparib) and bleomycin ( Table 1) . As expected (32, 37) , no correlation was observed for tubulin inhibitors (paclitaxel, docetaxel) and protein kinase inhibitors (erlotinib, crizotinib, vemurafenib), consistent with the selective implication of SLFN11 for cytotoxic response to DNA damaging drugs. 
Discussion
Here we provide readily usable and accessible genome-wide data for the NCI-60 cancer cell line methylome based on two independent determinations (Figure 1 ). Assignment of salient CpG sites for each gene (Supplemental Table 1 ) enables the extraction of those data using our CellMiner tools (14, 29) . We provide examples of how the DNA methylation data may be integrated with the extensive genomic and pharmacological databases for the NCI-60 (Figures 4, 5 and 6 ). We anticipate that these data and tools will enable exploration of i) the relevance of DNA methylation as a key regulator of gene expression, ii) its relationships with other forms of molecular data, and iii) genomic biomarkers for precision therapeutics. Determination of methylation status is a preferred approach for clinical samples because it provides robust information with which to evaluate cancer genomes (as it uses DNA rather than RNA, which tends to be unstable).
The examples we provide demonstrate that genome-wide access to DNA ), This demonstrates that, in the NCI-60,
cancer cells commonly inactivate CDKN2A by biallelic loss of CDKN2A (one allele by promoter methylation and the other by 9p21 chromosome deletion).
DNA methylation is also relevant to precision therapeutics, and, in this study, examples of two genes are presented: SLFN11 and MGMT. Both genes encode key factors that determine response to widely used DNA damaging agents, which remain a major component of the cancer armamentarium but lag behind protein kinase inhibitors in terms of predictive biomarkers. A relationship between SLFN11 transcript levels and pharmacological response has been demonstrated in both the NCI-60 and CCLE cancer cell lines (15, 32, 33, 41, 42) .
This relationship is both causal and broad in scope, affecting topoisomerase I inhibitors, topoisomerase II inhibitors, alkylating agents and DNA synthesis inhibitors (32, 37) . SLFN11 expression has recently been shown to be driven by ETS transcription factors (43) , which explain high SLFN11 expression in Ewing's sarcoma (33, 43) . Epigenetic inactivation of SLFN11, which accounts at least in part for frequent lack of expression of SLFN11 in many cancer cell lines including commonly used ones such as HeLa, U2OS and HCT116 (38) , and has recently been shown to have a robust and causal influence on resistance to platinumderived drugs such as cisplatin and carboplatin (15) . The present study expands this finding to eleven clinically relevant drugs (Table 1) . Correlations between the SLFN11 methylation levels and DNA damaging drug activities demonstrate the potential for using DNA methylation of SLFN11 in addition or in place of RNAand immunofluorescence-based assays for measuring SLFN11 expression, and testing the usefulness of SLFN11 as a novel predictive biomarker for drug activity in the clinical setting.
Temozolomide is approved for the treatment of glioblastomas because of the frequent inactivation of MGMT by promoter methylation in those tumors (34, 36, 44) . Methylome and gene expression analyses of the NCI-60 reveals that MGMT expression is frequently suppressed beyond CNS cancer cell lines (2 out of the 6 breast cancer cell lines, 2 out of the 7 colon, 2 or the 6 leukemia, 4 of the 10 melanomas, three of the 9 lung, and one of the 8 kidney cancer cell lines) ( Figure 5 and Supplemental Figure 2B ). Yet, promoter methylation explained only
5 of these 20 cell lines with low or no MGMT expression. These observations suggest that MGMT promoter methylation (36, 44) is actually insufficient to predict temozolomide activity and that other assays (transcripts or protein measurements) should be used to monitor patient candidates for temozolomide not only for glioblastomas but also outside of brain tumors.
In summary, the NCI-60 methylome adds to the preexisting molecular and pharmacological databases, which are publicly available and usable by noninformaticists at the Cellminer website (14) . They provide an additional translationally relevant piece in the molecular puzzle of understanding and predicting transcriptional regulation, and for the broader interplay among cancerassociated molecular and pharmacological parameters. Multiple red stars in the "Mutation" bar graph for a single cell line indicate deleterious variants occurring in more than one of the genes. Microsatellite instability for the cell lines is as described previously (12, 35) . Note the strong positive relationship between mutation of the mismatch repair genes (MLH1, MSH2, and MSH6) and microsatellite instability, and that this occurs in colon cell lines, as expected, and also in other cell line types. 
